RCR Clinical Oncology: Inspiring Future Academics in Clinical Oncology The National Radiotherapy Research Strategy David Sebag-Montefiore Professor of Clinical Oncology and Health Research Honorary Consultant Clinical Oncologist Deputy Chair CTRad [email protected]@MontefioreD
31
Embed
RCR Clinical Oncology: Inspiring Future Academics in ...€¦ · Inspiring Future Academics in Clinical Oncology The National Radiotherapy Research Strategy David Sebag-Montefiore
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
RCR Clinical Oncology: Inspiring Future Academics
in Clinical Oncology
The National Radiotherapy Research Strategy
David Sebag-Montefiore Professor of Clinical Oncology and Health Research
Practice Changing Radiation Therapy Trials for the Treatment of Cancer : where are we 150 years after the birth of Marie Curie? In Press BJC 2018
• Born 4th July 1867
• First woman to win a Nobel Prize
• First woman to win two Nobel Prizes and in two different scientific domains
• First female professor University of Paris
• Discovered Radium
• Founded Institute Curie
Authors • Marieke Thompson • Philip Poortmans • Anthony Chalmers • Corrine Faivre-Finn • Emma Hall • Robert Huddart • Yolande Lievens • David Sebag-Montefiore • Charlotte Coles
Practice Changing Trials – four disease “sites” n=47 trials; 47,890 patients
0 2 4 6 8 10 12
Breast
Lung
Prostate
Bladder
Rectal
Anal
UKNon UK
Last two decades
Development of clinical trial research proposals
• CTRad supports clinical trial research proposals development at all steps
• 184 trials reviewed at proposals guidance meetings up till June 16
Network of CTRad members within CSGs Consumers
CTRad provides reviews, feedback and guidance
Provision of expert reviewers for RT applications to CTAAC, NAC
184
Proposals submitted
Funded
58
CTRad Rated
48 87 22 27
Idea generation
Proposal development
Funding application
Funder peer review FUNDED
Lancet Oncology 2018 epub
Sharma et al Nature Reviews Clinical Oncology 2016
Alastair Greystoke, Gerry Hanna, Sarah Brown , on behalf of the CONCORDE study team
The proposed CONCORDE Study
Platform study of novel agents in COmbinatioN with COnventional RaDiothErapy in locally advanced disease
Leeds David Sebag-Montefiore
Sarah Brown Kevin Franks
Manchester Corrine Faivre Finn
James O’Connor Matthew Krebs
Oxford Ester Hammond Anderson Ryan
Glasgow Anthony Chalmers Stephen Harrow
Belfast Gerry Hanna
Richard Kennedy David G de Castro
Newcastle Alastair Greystoke
Chris Plummer
Cardiff Paul Shaw
Cambridge Susan Harden
11 ECMCs with RTTQA lung radiotherapy approval.
Primary endpoint: • DLTs within 3
months of RT
53.2Gy 28F
58.8Gy 28F
61.6Gy 28F
Ph II
Ph III
Pilot
T3/4 Nany,T2N1-3
Pilot/Ph II/PhIII
N=640
Leads – Hawkins and Sebag-Montefiore
ACT5
Primary end point :- 3yr locoregional failure
ACT3
Obsn
Margin ≤1mm
41.4Gy 23F
T1 N0/X Anal margin
Local excision
Phase II trial N=90
Lead – Renehan and Muirhead
50.4Gy 28F
41.4Gy 23F
ACT4
T1,T2<4cm N0/X
Randomised 2:1 Phase II trial
N=162
Leads – Adams and Harrison
PLATO - PersonaLising RadioTherapy dOse for Anal Cancer